Developer docs
API playgroundTry for free, no card

Search company profiles

FLUIDDA

Full company profile

uuid0007xnd

Namestring
FLUIDDA
Legal namestring
Fluidda NV
Websiteurl
fluidda.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

FLUIDDA (Fluidda NV) is a Belgian-founded (2005) medical technology and contract research organization that develops and commercializes Functional Respiratory Imaging (FRI), a proprietary methodology that combines high-resolution computed tomography (HRCT) scans with aerospace-engineered computational fluid dynamics (CFD) to produce patient-specific, regional biomarkers of the lungs and airways. These biomarkers — including airway resistance, ventilation mapping, lobar volume, emphysema quantification, blood vessel volume (BV5, BV5_10), and aerosol deposition — are used both as clinical-trial endpoints and as diagnostic inputs. The company monetizes FRI through two interlocking revenue streams: (i) CRO services for pharmaceutical and biotech sponsors (delivery optimization, clinical trial support, regulatory/bioequivalence pathway services, and scientific visualization) sold via multi-year, quote-based enterprise contracts, and (ii) a regulated medical device product, the Broncholab platform (FDA 510(k) cleared March 2020, CE marked June 2022, ISO 13485:2016 certified 2022), which delivers FRI parameters to radiologists and pulmonologists through an online portal on a subscription basis.

The company also operates a deep-learning module, RespiNet, launched in February 2023, that automates segmentation of lung lobes and airway trees in thin-slice CT, and applies machine-learning models that reportedly predict Bronchiolitis Obliterans Syndrome after lung transplantation with 85% accuracy. FLUIDDA serves a primarily enterprise customer base that includes TEVA, Novartis, Cipla, Respivant, and Merck, and runs clinical operations across approximately 60 countries through a network of roughly 500 clinical trial hospitals, with offices in Belgium (Kontich, headquarters), the United States (New York, Los Angeles), Portugal (Lisbon), and Singapore. Strategic partnerships include an exclusive 2022 collaboration with Nanopharm (an Aptar Pharma company) to enable alternative bioequivalence pathways for orally inhaled drug products, and a 2019 Asia/Pacific alliance with KreivoHealth. On 13 November 2025, FLUIDDA was acquired by Banook, a global provider of centralized cardiac safety, central imaging, and clinical endpoint management services, becoming a subsidiary within that group.

Short descriptiontext

FLUIDDA, founded in 2005 in Belgium, develops Functional Respiratory Imaging (FRI) combining HRCT scans and computational fluid dynamics for patient-specific respiratory analysis. The company serves pharmaceutical/biotech clients via CRO services and physicians through its FDA-cleared Broncholab diagnostic platform.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory imaging services, contract research services, lung function analysis, medical imaging software, drug development research
Industry3 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics
NAICS code3 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical and Medical Instrument Manufacturing339112
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Imaging Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CRO Services - Clinical Trials
TypeProfessional Services
Description

Fluidda provides contract research services to pharmaceutical and biotech companies for respiratory drug development and medical device development. Services include delivery optimization, clinical trial support, and scientific visualization. They offer turnkey services tailored to client needs in collaboration with dedicated partners.

fluidda.com
2Broncholab Platform (Medical Device)
TypeSubscription Recurring
Description

FDA-cleared and CE-certified diagnostic respiratory support tool for radiologists and pulmonologists. Provides quantitative FRI parameters for clinical diagnosis and monitoring of respiratory diseases.

fluidda.com
3Regulatory Pathway Services
TypeProfessional Services
Description

Services to help accelerate FDA approvals for orally inhaled generic products via alternative bioequivalence pathways, combining FRI with Nanopharm's SmartTrack platform for in-vitro/in-silico bioequivalence demonstrations.

fluidda.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1CRO Services - Delivery Optimization
ModelOtherBilling cadenceMulti-year contract
Notes

Services include evaluating aerosol deposition scenarios, simulating reality, and assessing infinite scenarios including anatomic, physiologic, and physicochemical variables. Pricing is quote-based for pharmaceutical and medical device companies.

fluidda.com
2CRO Services - Clinical Trials
ModelOtherBilling cadenceMulti-year contract
Notes

Provides state-of-the-art approach to bring clinical trials into the twenty-first century with up to 16 times fewer patients required. Turnkey contract research services tailored to needs. Pricing is quote-based for enterprise clients.

fluidda.com
3Broncholab Clinical Platform
ModelSubscriptionBilling cadenceAnnual
Notes

FDA-cleared and CE-certified platform for physicians providing FRI parameters. Available in EU and US markets. Pricing not publicly disclosed.

fluidda.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Broncholab
Description

FDA-cleared and CE-certified respiratory imaging platform that provides Functional Respiratory Imaging (FRI) parameters to physicians via an online platform to assist in diagnosing and monitoring of respiratory diseases.

fluidda.com
Core offering1 text field

FLUIDDA develops and applies Functional Respiratory Imaging (FRI), a proprietary technology that combines High-Resolution Computed Tomography (HRCT) scans with Computational Fluid Dynamics (CFD) to produce patient-specific 3D respiratory models and quantitative biomarkers. The company sells the FDA-cleared and CE-certified Broncholab medical device platform to physicians for clinical diagnosis and monitoring of respiratory diseases, and provides contract research services to pharmaceutical and biotech companies to accelerate and de-risk respiratory drug and medical device development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 16 times fewer patients needed to obtain clinically significant results in clinical trials
+3 more records
Product overview1 text field

Fluidda operates as both a CRO services company and medical technology developer, offering its proprietary Functional Respiratory Imaging (FRI) technology as the core platform. FRI combines HRCT scans with computational fluid dynamics (CFD) to provide patient-specific respiratory analysis. The product portfolio includes: Broncholab (FDA-cleared and CE-marked medical device platform for clinical diagnosis and monitoring), RespiNet (deep learning segmentation model for automated CT analysis), and three CRO service modules (Delivery Optimization, Clinical Trials, and Scientific Visualization) that leverage FRI technology to accelerate respiratory drug and device development.

Product and service4 records
1Broncholab
CategoryMedical Device Platform
Description

FDA-cleared and CE-marked medical device platform that delivers Functional Respiratory Imaging (FRI) parameters to physicians via an online portal to assist in diagnosing and monitoring respiratory diseases such as COPD, asthma, ILD, and pulmonary hypertension, including blood vessel measurements (BV5, BV5_10) for detecting pulmonary vascular remodeling.

2RespiNet
CategoryAI/ML Software Module
Description

Deep learning model for automated segmentation of lung lobes and airway tree in volumetric thin-slice CT scans, enabling automated analysis of lung structures for use in FRI pipelines and respiratory clinical research.

3CRO Respiratory Clinical Trial Services
CategoryContract Research Services
Description

Turnkey contract research services using Functional Respiratory Imaging biomarkers to accelerate respiratory drug and medical device clinical trials, including drug delivery optimization, clinical trial support (with up to 16 times fewer patients required), and scientific visualization of study results. Sold as multi-year engagements to enterprise pharmaceutical and biotech clients.

4Inhaled Drug Bioequivalence Pathway Services
CategoryRegulatory & Bioequivalence Services
Description

Regulatory pathway services that combine FLUIDDA's FRI platform with Nanopharm's SmartTrack in-vitro/PBPK platform to support alternative bioequivalence pathways for orally inhaled generic drug products, helping pharmaceutical clients accelerate FDA approvals.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagship/CoreTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

Banook, a leading global provider of centralized cardiac safety, central imaging and clinical endpoint management services, acquired Fluidda. The acquisition broadens Banook's expertise into respiratory clinical research and advanced imaging analytics, combining Fluidda's FRI platform with Banook's operational excellence in endpoint management.

2Nanopharm (Aptar Pharma)
Strategic tierFlagship/CoreTypeStrategic or Co-development PartnerAnnounced on2023-01-26
Description

Continued exclusive collaboration between Nanopharm and Fluidda to enable alternative bioequivalence pathways for orally inhaled drug products. Creates unique in-vitro in-silico platform combining SmartTrack with FRI technology.

fluidda.com
3Nanopharm (Aptar Pharma)
Strategic tierFlagship/CoreTypeStrategic or Co-development PartnerAnnounced on2022-09-22
Description

Exclusive collaboration to help accelerate regulatory pathway for orally inhaled products. Combining Fluidda's FRI (Functional Respiratory Imaging) platform with Nanopharm's SmartTrack platform for in-vitro/in-silico bioequivalence studies. First potential approval of OIDP using alternative bioequivalence approach pending.

fluidda.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

Consortium for sharing insights into mode of action of COVID-19 virus. Members include: LungBioTech, Fibrogen, Pliant, NXT, Theravance, Trudell, Galapagos, ThreeLakesFoundation, Neurimmune, MSD, AstraZeneca, Chiesi.

5KreivoHealth
Strategic tierMinorTypeGTM or Marketing Partner
Description

Collaboration established in 2019 for Asia/Pacific region expansion. Ernestine Chung from KreivoHealth supports Fluidda with clinical operations in Middle East, Central Asia and APAC region (ex-US and ex-EU), business development, and regulatory affairs predominantly in Singapore.

fluidda.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

First hospital to make structural use of Functional Respiratory Imaging to triage COVID-19 patients, starting November 2020. Demonstrated FRI's value in clinical triaging for optimal resource allocation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Multidisciplinary medical center for respiratory revalidation in Kontich, Belgium. Uses Fluidda's proprietary FRI technology for patient treatment optimization. Featured in Belgian newspaper De Standaard for innovative imaging technique.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fluidda CEO Jan De Backer and CSO Ben Lavon participate in OSIC working groups on pulmonary vascular manifestations and sequelae of COVID-19.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

VIDA provides AI-driven quantitative CT lung imaging software for clinical trial services and clinical practice, directly overlapping with Fluidda's FRI offering for respiratory drug development and diagnostic support.

TypeDirect peer
Description

Thirona develops advanced lung image analysis software (e.g., LungQ) for CT-based quantification in respiratory disease research and clinical use, competing head-to-head with Fluidda's FRI-based analysis services.

TypeBroad incumbent
Description

Banook is the strategic acquirer of Fluidda and a global provider of centralized cardiac safety, imaging, and clinical endpoint management services — directly comparable as a clinical trial CRO with imaging analytics capabilities.

TypeBroad incumbent
Description

Global clinical CRO offering respiratory and imaging endpoint services to pharma/biotech; comparable in its CRO-services customer base even though it does not focus on Fluidda's specific FRI modality.

TypeBroad incumbent
Description

Largest global CRO with extensive respiratory clinical trial expertise and an established imaging and real-world evidence practice; comparable to Fluidda on the customer side (top-tier pharma) rather than the technology side.

TypeEmerging player
Description

AI medical imaging cloud platform with FDA-cleared analytics for chest CT and other modalities; partial overlap with Fluidda as it brings AI-driven imaging quantification to clinical practice and trials.

TypeEmerging player
Description

AI imaging platform focused on radiology workflow and triage across multiple organs; comparable as a peer AI imaging company serving hospital systems, though not focused on respiratory research endpoints.

8Nanopharm (Aptar Pharma)
TypeOthers
Description

Strategic partner of Fluidda and developer of SmartTrack in-vitro/PBPK modeling for orally inhaled drug products; comparable as an ecosystem participant in the OIDP bioequivalence pathway alongside FRI.

TypeOthers
Description

Non-profit consortium advancing imaging-based diagnosis and treatment of interstitial lung diseases; Fluidda's CEO and CSO participate in OSIC working groups, making it a directly relevant industry consortium peer.

TypeEmerging player
Description

Provider of image processing and analysis software for CT-based lung and other diagnostic workflows, with similar use cases in clinical research and pharmaceutical trials to Fluidda's FRI platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FLUIDDA

Medical Imaging Softwarefluidda.com

FLUIDDA, founded in 2005 in Belgium, develops Functional Respiratory Imaging (FRI) combining HRCT scans and computational fluid dynamics for patient-specific respiratory analysis. The company serves pharmaceutical/biotech clients via CRO services and physicians through its FDA-cleared Broncholab diagnostic platform.

What FLUIDDA does

FLUIDDA (Fluidda NV) is a Belgian-founded (2005) medical technology and contract research organization that develops and commercializes Functional Respiratory Imaging (FRI), a proprietary methodology that combines high-resolution computed tomography (HRCT) scans with aerospace-engineered computational fluid dynamics (CFD) to produce patient-specific, regional biomarkers of the lungs and airways. These biomarkers — including airway resistance, ventilation mapping, lobar volume, emphysema quantification, blood vessel volume (BV5, BV5_10), and aerosol deposition — are used both as clinical-trial endpoints and as diagnostic inputs. The company monetizes FRI through two interlocking revenue streams: (i) CRO services for pharmaceutical and biotech sponsors (delivery optimization, clinical trial support, regulatory/bioequivalence pathway services, and scientific visualization) sold via multi-year, quote-based enterprise contracts, and (ii) a regulated medical device product, the Broncholab platform (FDA 510(k) cleared March 2020, CE marked June 2022, ISO 13485:2016 certified 2022), which delivers FRI parameters to radiologists and pulmonologists through an online portal on a subscription basis.

The company also operates a deep-learning module, RespiNet, launched in February 2023, that automates segmentation of lung lobes and airway trees in thin-slice CT, and applies machine-learning models that reportedly predict Bronchiolitis Obliterans Syndrome after lung transplantation with 85% accuracy. FLUIDDA serves a primarily enterprise customer base that includes TEVA, Novartis, Cipla, Respivant, and Merck, and runs clinical operations across approximately 60 countries through a network of roughly 500 clinical trial hospitals, with offices in Belgium (Kontich, headquarters), the United States (New York, Los Angeles), Portugal (Lisbon), and Singapore. Strategic partnerships include an exclusive 2022 collaboration with Nanopharm (an Aptar Pharma company) to enable alternative bioequivalence pathways for orally inhaled drug products, and a 2019 Asia/Pacific alliance with KreivoHealth. On 13 November 2025, FLUIDDA was acquired by Banook, a global provider of centralized cardiac safety, central imaging, and clinical endpoint management services, becoming a subsidiary within that group.

FLUIDDA firmographics

Firmographics
Name
FLUIDDA
Legal name
Fluidda NV
Website
https://fluidda.com
Company type
Private
Founded year
2005
Operating status
Acquired
Headcount range
11–50 employees
Short description
FLUIDDA, founded in 2005 in Belgium, develops Functional Respiratory Imaging (FRI) combining HRCT scans and computational fluid dynamics for patient-specific respiratory analysis. The company serves pharmaceutical/biotech clients via CRO services and physicians through its FDA-cleared Broncholab diagnostic platform.
Ownership category
akta.pro rank

FLUIDDA industry classification

Industry
Product category
Medical Imaging Software
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics

Keywords

  • Respiratory imaging services
  • Contract research services
  • Lung function analysis
  • Medical imaging software
  • Drug development research

Where FLUIDDA is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices5 records

Markets served

FLUIDDA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. CRO Services - Clinical Trials: Fluidda provides contract research services to pharmaceutical and biotech companies for respiratory drug development and medical device development. Services include delivery optimization, clinical trial support, and scientific visualization. They offer turnkey services tailored to client needs in collaboration with dedicated partners.
  2. Broncholab Platform (Medical Device): FDA-cleared and CE-certified diagnostic respiratory support tool for radiologists and pulmonologists. Provides quantitative FRI parameters for clinical diagnosis and monitoring of respiratory diseases.
  3. Regulatory Pathway Services: Services to help accelerate FDA approvals for orally inhaled generic products via alternative bioequivalence pathways, combining FRI with Nanopharm's SmartTrack platform for in-vitro/in-silico bioequivalence demonstrations.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCRO Services - Delivery Optimization
OtherMulti-year contractCRO Services - Clinical Trials
SubscriptionAnnualBroncholab Clinical Platform

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

FLUIDDA product offering

Product offering

Core offering

FLUIDDA develops and applies Functional Respiratory Imaging (FRI), a proprietary technology that combines High-Resolution Computed Tomography (HRCT) scans with Computational Fluid Dynamics (CFD) to produce patient-specific 3D respiratory models and quantitative biomarkers. The company sells the FDA-cleared and CE-certified Broncholab medical device platform to physicians for clinical diagnosis and monitoring of respiratory diseases, and provides contract research services to pharmaceutical and biotech companies to accelerate and de-risk respiratory drug and medical device development.

Product overview

Fluidda operates as both a CRO services company and medical technology developer, offering its proprietary Functional Respiratory Imaging (FRI) technology as the core platform. FRI combines HRCT scans with computational fluid dynamics (CFD) to provide patient-specific respiratory analysis. The product portfolio includes: Broncholab (FDA-cleared and CE-marked medical device platform for clinical diagnosis and monitoring), RespiNet (deep learning segmentation model for automated CT analysis), and three CRO service modules (Delivery Optimization, Clinical Trials, and Scientific Visualization) that leverage FRI technology to accelerate respiratory drug and device development.

Differentiator

Problem solved

Functional benefit

Brands

  • Broncholab: FDA-cleared and CE-certified respiratory imaging platform that provides Functional Respiratory Imaging (FRI) parameters to physicians via an online platform to assist in diagnosing and monitoring of respiratory diseases.

Products and services

  • Broncholab FDA-cleared and CE-marked medical device platform that delivers Functional Respiratory Imaging (FRI) parameters to physicians via an online portal to assist in diagnosing and monitoring respiratory diseases such as COPD, asthma, ILD, and pulmonary hypertension, including blood vessel measurements (BV5, BV5_10) for detecting pulmonary vascular remodeling.
  • RespiNet Deep learning model for automated segmentation of lung lobes and airway tree in volumetric thin-slice CT scans, enabling automated analysis of lung structures for use in FRI pipelines and respiratory clinical research.
  • CRO Respiratory Clinical Trial Services Turnkey contract research services using Functional Respiratory Imaging biomarkers to accelerate respiratory drug and medical device clinical trials, including drug delivery optimization, clinical trial support (with up to 16 times fewer patients required), and scientific visualization of study results. Sold as multi-year engagements to enterprise pharmaceutical and biotech clients.
  • Inhaled Drug Bioequivalence Pathway Services Regulatory pathway services that combine FLUIDDA's FRI platform with Nanopharm's SmartTrack in-vitro/PBPK platform to support alternative bioequivalence pathways for orally inhaled generic drug products, helping pharmaceutical clients accelerate FDA approvals.

Quantifiable outcome

  • Up to 16 times fewer patients needed to obtain clinically significant results in clinical trials
  • +3 more outcomes

Companies that use FLUIDDA

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

FLUIDDA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature5 records

FLUIDDA partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship/core and minor.

  • Banookflagship/coreStrategic or Co-development Partner · 13 November 2025Banook, a leading global provider of centralized cardiac safety, central imaging and clinical endpoint management services, acquired Fluidda. The acquisition broadens Banook's expertise into respiratory clinical research and advanced imaging analytics, combining Fluidda's FRI platform with Banook's operational excellence in endpoint management.
  • Nanopharm (Aptar Pharma)flagship/coreStrategic or Co-development Partner · 26 January 2023Continued exclusive collaboration between Nanopharm and Fluidda to enable alternative bioequivalence pathways for orally inhaled drug products. Creates unique in-vitro in-silico platform combining SmartTrack with FRI technology.
  • Nanopharm (Aptar Pharma)flagship/coreStrategic or Co-development Partner · 22 September 2022Exclusive collaboration to help accelerate regulatory pathway for orally inhaled products. Combining Fluidda's FRI (Functional Respiratory Imaging) platform with Nanopharm's SmartTrack platform for in-vitro/in-silico bioequivalence studies. First potential approval of OIDP using alternative bioequivalence approach pending.
  • COVID-19 Consortium MembersminorStrategic or Co-development Partner · 1 April 2020Consortium for sharing insights into mode of action of COVID-19 virus. Members include: LungBioTech, Fibrogen, Pliant, NXT, Theravance, Trudell, Galapagos, ThreeLakesFoundation, Neurimmune, MSD, AstraZeneca, Chiesi.
  • KreivoHealthminorGTM or Marketing PartnerCollaboration established in 2019 for Asia/Pacific region expansion. Ernestine Chung from KreivoHealth supports Fluidda with clinical operations in Middle East, Central Asia and APAC region (ex-US and ex-EU), business development, and regulatory affairs predominantly in Singapore.
  • AZ Delta HospitalminorStrategic or Co-development PartnerFirst hospital to make structural use of Functional Respiratory Imaging to triage COVID-19 patients, starting November 2020. Demonstrated FRI's value in clinical triaging for optimal resource allocation.
  • MedImproveminorStrategic or Co-development PartnerMultidisciplinary medical center for respiratory revalidation in Kontich, Belgium. Uses Fluidda's proprietary FRI technology for patient treatment optimization. Featured in Belgian newspaper De Standaard for innovative imaging technique.
  • Open Source Imaging Consortium (OSIC)minorStrategic or Co-development PartnerFluidda CEO Jan De Backer and CSO Ben Lavon participate in OSIC working groups on pulmonary vascular manifestations and sequelae of COVID-19.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

FLUIDDA competitors and assessment

Company assessment

Direct peers

  • VIDA Diagnostics: VIDA provides AI-driven quantitative CT lung imaging software for clinical trial services and clinical practice, directly overlapping with Fluidda's FRI offering for respiratory drug development and diagnostic support.
  • Thirona: Thirona develops advanced lung image analysis software (e.g., LungQ) for CT-based quantification in respiratory disease research and clinical use, competing head-to-head with Fluidda's FRI-based analysis services.

Broad incumbents

  • Banook: Banook is the strategic acquirer of Fluidda and a global provider of centralized cardiac safety, imaging, and clinical endpoint management services — directly comparable as a clinical trial CRO with imaging analytics capabilities.
  • ICON plc: Global clinical CRO offering respiratory and imaging endpoint services to pharma/biotech; comparable in its CRO-services customer base even though it does not focus on Fluidda's specific FRI modality.
  • IQVIA: Largest global CRO with extensive respiratory clinical trial expertise and an established imaging and real-world evidence practice; comparable to Fluidda on the customer side (top-tier pharma) rather than the technology side.

Emerging players

  • Arterys: AI medical imaging cloud platform with FDA-cleared analytics for chest CT and other modalities; partial overlap with Fluidda as it brings AI-driven imaging quantification to clinical practice and trials.
  • Aidoc: AI imaging platform focused on radiology workflow and triage across multiple organs; comparable as a peer AI imaging company serving hospital systems, though not focused on respiratory research endpoints.
  • MeVis Medical Solutions: Provider of image processing and analysis software for CT-based lung and other diagnostic workflows, with similar use cases in clinical research and pharmaceutical trials to Fluidda's FRI platform.

Others

  • Nanopharm (Aptar Pharma): Strategic partner of Fluidda and developer of SmartTrack in-vitro/PBPK modeling for orally inhaled drug products; comparable as an ecosystem participant in the OIDP bioequivalence pathway alongside FRI.
  • Open Source Imaging Consortium (OSIC): Non-profit consortium advancing imaging-based diagnosis and treatment of interstitial lung diseases; Fluidda's CEO and CSO participate in OSIC working groups, making it a directly relevant industry consortium peer.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

FLUIDDA social profiles

Digital presence

FLUIDDA compliance and trust

Trust signal

Compliance3 records

FLUIDDA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FLUIDDA leadership team

Management profile

Number of profiles

Profiles10 records

FLUIDDA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FLUIDDA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FLUIDDA

What does FLUIDDA do?

FLUIDDA develops and applies Functional Respiratory Imaging (FRI), a proprietary technology that combines High-Resolution Computed Tomography (HRCT) scans with Computational Fluid Dynamics (CFD) to produce patient-specific 3D respiratory models and quantitative biomarkers. The company sells the FDA-cleared and CE-certified Broncholab medical device platform to physicians for clinical diagnosis and monitoring of respiratory diseases, and provides contract research services to pharmaceutical and biotech companies to accelerate and de-risk respiratory drug and medical device development.

Is FLUIDDA a public or private company?

FLUIDDA is a private company. It is classified as corporate owned and is currently acquired.

When was FLUIDDA founded?

FLUIDDA was founded in 2005. It employs 11 to 50 people.

Where is FLUIDDA based?

FLUIDDA is headquartered in New York, United States, in the North America region.

How does FLUIDDA make money?

Three revenue lines are on record. CRO Services - Clinical Trials are the primary driver. The others are broncholab Platform (Medical Device) and regulatory Pathway Services.

Who are FLUIDDA's main competitors?

Direct peers on record are VIDA Diagnostics and Thirona. Broad incumbents are Banook, ICON plc and IQVIA. Emerging players are Arterys, Aidoc and MeVis Medical Solutions. Others are Nanopharm (Aptar Pharma) and Open Source Imaging Consortium (OSIC).

Does FLUIDDA have an API?

No public API is recorded for FLUIDDA.

What industry is FLUIDDA in?

FLUIDDA's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLAHABAI, Imaging Informatics & Workflow (PACS/RIS/VNA). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals